Abstract
Diseases of the central nervous system (CNS) affect millions of people worldwide and disease burden is increasing with an aging population. Yet, there are few medicines available to diagnose and treat neurological disorders and progress on developing new medicines has been limited. One major challenge is the narrow therapeutic window of payloads that act in the CNS – significant transport barriers restrict bioavailability yet the CNS is sensitive to toxicity. Bioresponsive nanomaterials can be engineered to activate based on context and encode sophisticated functions. Contexts that activate bioresponsive nanomaterials can be specific to the temporal and spatial dynamics of healthy and pathological biological processes, and thus offer approaches to increase efficacy of payloads while mitigating off-target effects. In this chapter, environment cues specific to CNS diseases or within subcellular compartments will be discussed and examples of bioresponsive nanomaterials that have been engineered to respond to these cues will be presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams, D., et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. The New England Journal of Medicine, 379, 11–21.
Adibhatla, R. M., & Hatcher, J. F. (2010). Lipid oxidation and peroxidation in CNS health and disease: From molecular mechanisms to therapeutic opportunities. Antioxidants & Redox Signaling, 12, 125–169.
Agrawal, M., et al. (2020). Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. Journal of Controlled Release, 327, 235–265.
Aguilera, T. A., Olson, E. S., Timmers, M. M., Jiang, T., & Tsien, R. Y. (2009). Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integrative Biology, 1, 371–381.
Akinc, A., et al. (2019). The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nature Nanotechnology, 14, 1084–1087.
Alberts, B., et al. (2002). Transport from the trans Golgi network to lysosomes. Molecular Biology of the Cell 4th Edition.
Anderson, R. E., & Sundt, T. M. (1983). Brain pH in focal cerebral ischemia and the protective effects of barbiturate anesthesia. https://journals.sagepub.com/doi/abs/10.1038/jcbfm.1983.76
Anna, R., et al. (2006). Increased brain expression of matrix Metalloproteinase-9 after ischemic and Hemorrhagic human stroke. Stroke, 37, 1399–1406.
Anselmo, A. C., & Mitragotri, S. (2016). Nanoparticles in the clinic. Bioengineering & Translational Medicine, 1, 10–29.
Appelros, P., Stegmayr, B., & Terént, A. (2009). Sex differences in stroke epidemiology. Stroke, 40, 1082–1090.
Attenello, F. J., et al. (2008). Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience. Annals of Surgical Oncology, 15, 2887.
Azbill, R. D., Mu, X., Bruce-Keller, A. J., Mattson, M. P., & Springer, J. E. (1997). Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury. Brain Research, 765, 283–290.
Badeau, B. A., & DeForest, C. A. (2019). Programming stimuli-responsive behavior into biomaterials. Annual Review of Biomedical Engineering, 21, 241–265.
Badeau, B. A., Comerford, M. P., Arakawa, C. K., Shadish, J. A., & DeForest, C. A. (2018). Engineered modular biomaterial logic gates for environmentally triggered therapeutic delivery. Nature Chemistry, 10, 251–258.
Basurto-Islas, G., Grundke-Iqbal, I., Tung, Y. C., Liu, F., & Iqbal, K. (2013). Activation of Asparaginyl endopeptidase leads to tau hyperphosphorylation in Alzheimer disease*. The Journal of Biological Chemistry, 288, 17495–17507.
Bevers, M. B., & Neumar, R. W. (2008). Mechanistic role of calpains in postischemic neurodegeneration. The Journal of Cerebral Blood Flow & Metabolism, 28, 655–673.
Bharadwaj, V. N., et al. (2020). Sex-dependent macromolecule and nanoparticle delivery in experimental brain injury. Tissue Engineering. Part A, 26, 688–701.
Bing-Qiao, Z., Emiri, T., & Lo Eng, H. (2007). Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke. Stroke, 38, 748–752.
Blum, A. P., et al. (2015). Stimuli-responsive nanomaterials for biomedical applications. Journal of the American Chemical Society, 137, 2140–2154.
Bo, C., Cheng, Q., Kai, Y., & Lyden Patrick, D. (2010). Thrombin mediates severe neurovascular injury during ischemia. Stroke, 41, 2348–2352.
Bordt, E. A., & Polster, B. M. (2014). NADPH oxidase- and mitochondria-derived reactive oxygen species in proinflammatory microglial activation: A bipartisan affair? Free Radical Biology & Medicine, 76, 34–46.
Carreau, A., Hafny-Rahbi, B. E., Matejuk, A., Grillon, C., & Kieda, C. (2011). Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. Journal of Cellular and Molecular Medicine, 15, 1239–1253.
Chen, B., et al. (2012). Thrombin activity associated with neuronal damage during acute focal ischemia. The Journal of Neuroscience, 32, 7622–7631.
Chen, R., et al. (2018). Reactive oxygen species formation in the brain at different oxygen levels: The role of hypoxia inducible factors. Frontiers in Cell and Development Biology, 6, 132.
Chesler, M. (2003). Regulation and modulation of pH in the brain. Physiological Reviews, 83, 1183–1221.
Clark, A. J., & Davis, M. E. (2015). Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proceedings of the National Academy of Sciences, 112, 12486–12491.
Cook, A. B., & Decuzzi, P. (2021). Harnessing endogenous stimuli for responsive materials in theranostics. ACS Nano, 15, 2068–2098.
Corbet, C., & Feron, O. (2017). Tumour acidosis: From the passenger to the driver’s seat. Nature Reviews. Cancer, 17, 577–593.
Dall, E., & Brandstetter, H. (2016). Structure and function of legumain in health and disease. Biochimie, 122, 126–150.
Daneman, R. (2012). The blood–brain barrier in health and disease. Annals of Neurology, 72, 648–672.
Desnoyers, L. R., et al. (2013). Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3006682
Doronina, S. O., et al. (2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology, 21, 778–784.
Edwards, D. I. (1993). Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action. Journal of Antimicrobial Chemotherapy, 31, 9–20.
Ellgaard, L., Sevier, C. S., & Bulleid, N. J. (2018). How are proteins reduced in the endoplasmic reticulum? Trends in Biochemical Sciences, 43, 32–43.
Ellingson, B. M., et al. (2019). pH-weighted molecular MRI in human traumatic brain injury (TBI) using amine proton chemical exchange saturation transfer echoplanar imaging (CEST EPI). NeuroImage Clinical, 22, 101736.
Forman, H. J., Zhang, H., & Rinna, A. (2009). Glutathione: Overview of its protective roles, measurement, and biosynthesis. Molecular Aspects of Medicine, 30, 1–12.
Forsyth, P. A., et al. (1999). Gelatinase-a (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. British Journal of Cancer, 79, 1828–1835.
Furtado, D., et al. (2018). Overcoming the blood–brain barrier: The role of nanomaterials in treating neurological diseases. Advanced Materials, 30, 1801362.
Gamcsik, M. P., Kasibhatla, M. S., Teeter, S. D., & Colvin, O. M. (2012). Glutathione levels in human tumors. Biomark Biochem Indic Expo Response Susceptibility Chem, 17, 671–691.
Ge, J., Neofytou, E., Cahill, T. J., Beygui, R. E., & Zare, R. N. (2012). Drug release from electric-field-responsive nanoparticles. ACS Nano, 6, 227–233.
Geng, J., Li, M., Wu, L., Chen, C., & Qu, X. (2012). Mesoporous silica nanoparticle-based H2O2 responsive controlled-release system used for Alzheimer’s disease treatment. Advanced Healthcare Materials, 1, 332–336.
Gerweck, L. E., & Seetharaman, K. (1996). Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Research, 56, 1194–1198.
Gidday, J. M., et al. (2005). Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. American Journal of Physiology-Heart and Circulatory Physiology, 289, H558–H568.
Gu, G., et al. (2013). PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials, 34, 196–208.
Guevara, R., Gianotti, M., Oliver, J., & Roca, P. (2011). Age and sex-related changes in rat brain mitochondrial oxidative status. Experimental Gerontology, 46, 923–928.
Guo, X., et al. (2018). Thrombin-responsive, brain-targeting nanoparticles for improved stroke therapy. ACS Nano, 12, 8723–8732.
Hajipour, M. J., et al. (2021). Sex as an important factor in nanomedicine. Nature Communications, 12, 2984.
Han, L., et al. (2019). Systemic delivery of monoclonal antibodies to the central nervous system for brain tumor therapy. Advanced Materials, 31, 1805697.
Harris, T. J., von Maltzahn, G., Derfus, A. M., Ruoslahti, E., & Bhatia, S. N. (2006). Proteolytic actuation of nanoparticle self-assembly. Angewandte Chemie, International Edition, 45, 3161–3165.
Harris, R. J., et al. (2018). Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magnetic Resonance in Medicine, 80, 1962–1978.
Heller, J., Baker, R. W., Gale, R. M., & Rodin, J. O. (1978). Controlled drug release by polymer dissolution. I. Partial esters of maleic anhydride copolymers—properties and theory. Journal of Applied Polymer Science, 22, 1991–2009.
Hoffman, A. S. (2013). Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation. Advanced Drug Delivery Reviews, 65, 10–16.
Horstmann, S., Kalb, P., Koziol, J., Gardner, H., & Wagner, S. (2003). Profiles of matrix Metalloproteinases, their inhibitors, and Laminin in stroke patients. Stroke, 34, 2165–2170.
Hua, L., et al. (2018). Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy. Theranostics, 8, 5088–5105.
Huang, G., et al. (2020). PET imaging of occult tumours by temporal integration of tumour-acidosis signals from pH-sensitive 64 cu-labelled polymers. Nature Biomedical Engineering, 4, 314–324.
Hyun, H., et al. (2013). Ischemic brain imaging using fluorescent gold nanoprobes sensitive to reactive oxygen species. Journal of Controlled Release, 170, 352–357.
Ishizaki, T., et al. (2010). The Asparaginyl endopeptidase Legumain after experimental stroke. Journal of Cerebral Blood Flow and Metabolism, 30, 1756–1766.
Jiang, T., et al. (2004). Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proceedings of the National Academy of Sciences, 101, 17867–17872.
Jiang, L., et al. (2013). pH/temperature sensitive magnetic nanogels conjugated with Cy5.5-labled lactoferrin for MR and fluorescence imaging of glioma in rats. Biomaterials, 34, 7418–7428.
Justicia, C., et al. (2003). Neutrophil infiltration increases matrix Metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. Journal of Cerebral Blood Flow and Metabolism, 23, 1430–1440.
Kandell, R. M., Waggoner, L. E., & Kwon, E. J. (2021). Nanomedicine for acute brain injuries: Insight from decades of cancer Nanomedicine. Molecular Pharmaceutics, 18, 522–538.
Kapoor, M., Sharma, S., Sandhir, R., & Nehru, B. (2019). Temporal changes in physiological and molecular markers in various brain regions following transient global ischemia in rats. Molecular Biology Reports, 46, 6215–6230.
Kavanaugh, W. M. (2020). Antibody prodrugs for cancer. Expert Opinion on Biological Therapy, 20, 163–171.
Kennedy, L., Sandhu, J. K., Harper, M.-E., & Cuperlovic-Culf, M. (2020). Role of glutathione in cancer: From mechanisms to therapies. Biomolecules, 10, E1429.
Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018). Recent progress of drug nanoformulations targeting to brain. Journal of Controlled Release, 291, 37–64.
Kim, A. J., Woodworth, G. F., Boylan, N. J., Suk, J. S., & Hanes, J. (2014). Highly compacted pH-responsive DNA nanoparticles mediate transgene silencing in experimental glioma. Journal of Materials Chemistry B, 2, 8165–8173.
Knoblach, S. M., & Faden, A. I. (2005). Proteases in Traumatic Brain Injury. In U. Lendeckel & N. M. Hooper (Eds.), Proteases in the brain (Vol. 3, pp. 79–108). Springer.
Korenchan, D. E., & Flavell, R. R. (2019). Spatiotemporal pH heterogeneity as a promoter of cancer progression and therapeutic resistance. Cancers, 11, 1026.
Kudryashev, J. A., Waggoner, L. E., Leng, H. T., Mininni, N. H., & Kwon, E. J. (2020). An activity-based Nanosensor for traumatic brain injury. ACS Sensors, 5, 686–692.
Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R., & van der Meel, R. (2019). Lipid nanoparticle Technology for Clinical Translation of siRNA therapeutics. Accounts of Chemical Research, 52, 2435–2444.
Kwon, E. J., Lo, J. H., & Bhatia, S. N. (2015). Smart nanosystems: Bio-inspired technologies that interact with the host environment. Proceedings of the National Academy of Sciences, 112, 14460–14466.
Lee, H., Lee, K., Kim, I. K., & Park, T. G. (2008). Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes. Biomaterials, 29, 4709–4718.
Levesque, S., et al. (2010). Reactive microgliosis: Extracellular-calpain and microglia-mediated dopaminergic neurotoxicity. Brain, 133, 808–821.
Li, W., & Yang, S. (2016). Targeting oxidative stress for the treatment of ischemic stroke: Upstream and downstream therapeutic strategies. Brain Circulation, 2, 153–163.
Lin, H.-R., & Sung, K. C. (2000). Carbopol/pluronic phase change solutions for ophthalmic drug delivery. Journal of Controlled Release, 69, 379–388.
Liu, Y., & Lu, W. (2012). Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opinion on Drug Delivery, 9, 671–686.
Liu, C., Sun, C., Huang, H., Janda, K., & Edgington, T. (2003). Overexpression of Legumain in Tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Research, 63, 2957–2964.
Liu, J., Liu, M. C., & Wang, K. K. W. (2008). Calpain in the CNS: From synaptic function to neurotoxicity. Science Signaling, 1, re1–re1.
Lo, E. H., Wang, X., & Cuzner, M. L. (2002). Extracellular proteolysis in brain injury and inflammation: Role for plasminogen activators and matrix metalloproteinases. Journal of Neuroscience Research, 69, 1–9.
Lo, J. H., Kwon, E. J., Zhang, A. Q., Singhal, P., & Bhatia, S. N. (2016). Comparison of modular PEG incorporation strategies for stabilization of peptide–siRNA Nanocomplexes. Bioconjugate Chemistry, 27, 2323–2331.
López-Otín, C., & Bond, J. S. (2008). Proteases: Multifunctional enzymes in life and disease. The Journal of Biological Chemistry, 283, 30433–30437.
Lu, Y., Aimetti, A. A., Langer, R., & Gu, Z. (2016). Bioresponsive materials. Nature Reviews Materials, 2, 1–17.
Lu, Y., et al. (2019a). Microenvironment Remodeling micelles for Alzheimer’s disease therapy by early modulation of activated microglia. Advancement of Science, 6, 1801586.
Lu, Y., et al. (2019b). Microthrombus-targeting micelles for neurovascular Remodeling and enhanced microcirculatory perfusion in acute ischemic stroke. Advanced Materials, 31, 1808361.
Lv, W., et al. (2018). Bioengineered Boronic Ester modified dextran polymer nanoparticles as reactive oxygen species responsive Nanocarrier for ischemic stroke treatment. ACS Nano, 12, 5417–5426.
Lyass, O., Hubert, A., & Gabizon, A. A. (2001). Phase I study of Doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clinical Cancer Research, 7, 3040–3046.
Ma, L., Shen, Y.-Q., Khatri, H. P., & Schachner, M. (2014). The Asparaginyl endopeptidase Legumain is essential for functional recovery after spinal cord injury in adult zebrafish. PLoS One, 9.
MacKay, J. A., et al. (2008). HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery. Molecular Therapy, 16, 893–900.
Malorni, W., Campesi, I., Straface, E., Vella, S., & Franconi, F. (2007). Redox features of the cell: A gender perspective. Antioxidants & Redox Signaling, 9, 1779–1802.
Manoharan, S., et al. (2016). The role of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease: A mini review. Oxidative Medicine and Cellular Longevity, 8590578(2016).
Mitchell, M. J., et al. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews. Drug Discovery, 20, 101–124.
Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12, 991–1003.
Nance, E. A., et al. (2012). A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Science Translational Medicine, 4, 149ra119–149ra119.
O’Riordan, L. S., Laughlin, K. M., & Lowry, P. J. (2016). In vitro physiological performance factors of a catalase-based biosensor for real-time electrochemical detection of brain hydrogen peroxide in freely-moving animals. Analytical Methods, 8, 7614–7622.
Pardridge, W. M. (2005). The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2, 3–14.
Polack, F. P., et al. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. The New England Journal of Medicine, 383, 2603–2615.
Purcell, B. P., et al. (2014). Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nature Materials, 13, 653–661.
Quader, S., et al. (2021). Supramolecularly enabled pH- triggered drug action at tumor microenvironment potentiates nanomedicine efficacy against glioblastoma. Biomaterials, 267, 120463.
Rajkovic, O., et al. (2019). Reactive oxygen species-responsive nanoparticles for the treatment of ischemic stroke. Advances in Therapy, 2, 1900038.
Ramírez-García, P. D., et al. (2019). A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain. Nature Nanotechnology, 14, 1150–1159.
Rao, J. S. (2003). Molecular mechanisms of glioma invasiveness: The role of proteases. Nature Reviews. Cancer, 3, 489–501.
Rawlings, N. D., et al. (2018). The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Research, 46, D624–D632.
Ren, J., et al. (2020). Increased cross-linking micelle retention in the brain of Alzheimer’s disease mice by elevated asparagine endopeptidase protease responsive aggregation. Biomaterials Science, 8, 6533–6544.
Rizwan, M., et al. (2017). pH sensitive hydrogels in drug delivery: Brief history, properties, swelling, and release mechanism, material selection and applications. Polymers, 9, 137.
Rodrigo, R., et al. (2013). Oxidative stress and pathophysiology of ischemic stroke: Novel therapeutic opportunities. CNS & Neurological Disorders Drug Targets, 12, 698–714.
Rodríguez-Rodríguez, A., Egea-Guerrero, J. J., Murillo-Cabezas, F., & Carrillo-Vico, A. (2014). Oxidative stress in traumatic brain injury. Current Medicinal Chemistry, 21, 1201–1211.
Rosenberg, G. A. (2009). Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurology, 8, 205–216.
Ruan, S., et al. (2015). Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials, 37, 425–435.
Ruan, S., et al. (2016). Increased gold nanoparticle retention in brain Tumors by in situ enzyme-induced aggregation. ACS Nano, 10, 10086–10098.
Ruan, S., et al. (2018). Acid-responsive transferrin dissociation and GLUT mediated exocytosis for increased blood–brain barrier Transcytosis and programmed glioma targeting delivery. Advanced Functional Materials, 28, 1802227.
Saatman, K. E., Creed, J., & Raghupathi, R. (2010). Calpain as a therapeutic target in traumatic brain injury. Neurotherapeutics, 7, 31–42.
Safra, T., et al. (2000). Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Annals of Oncology, 11, 1029–1034.
Sato, T., et al. (2006). Neutrophil elastase and cancer. Surgical Oncology, 15, 217–222.
Selakovic, V., Korenic, A., & Radenovic, L. (2011). Spatial and temporal patterns of oxidative stress in the brain of gerbils submitted to different duration of global cerebral ischemia. International Journal of Developmental Neuroscience, 29, 645–654.
Selvin, P. R. (2000). The renaissance of fluorescence resonance energy transfer. Nature Structural Biology, 7, 730–734.
Semple, B. D., Trivedi, A., Gimlin, K., & Noble-Haeusslein, L. J. (2015). Neutrophil elastase mediates acute pathogenesis and is a determinant of long-term behavioral recovery after traumatic injury to the immature brain. Neurobiology of Disease, 74, 263–280.
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews. Cancer, 17, 20–37.
Siesjö, B. K. (1992). Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. Journal of Neurosurgery, 77, 169–184.
Simon, D. W., et al. (2017a). The far-reaching scope of neuroinflammation after traumatic brain injury. Nature Reviews. Neurology, 13, 171–191.
Simon, D., et al. (2017b). Plasma matrix metalloproteinase-9 levels predict intensive care unit mortality early after severe traumatic brain injury. Brain Injury, 31, 390–395.
Simpkins, J. W., & Dykens, J. A. (2008). Mitochondrial mechanisms of estrogen neuroprotection. Brain Research Reviews, 57, 421–430.
Smith, S. L., Andrus, P. K., Zhang, J.-R., & Hall, E. D. (1994). Direct measurement of hydroxyl radicals, lipid peroxidation, and blood–brain barrier disruption following unilateral cortical impact head injury in the rat. Journal of Neurotrauma, 11, 393–404.
Stowe, A. M., et al. (2009). Neutrophil elastase and neurovascular injury following focal stroke and reperfusion. Neurobiology of Disease, 35, 82–90.
Svirskis, D., Travas-Sejdic, J., Rodgers, A., & Garg, S. (2010). Electrochemically controlled drug delivery based on intrinsically conducting polymers. Journal of Controlled Release, 146, 6–15.
Tejima, E., et al. (2007). Astrocytic induction of matrix Metalloproteinase-9 and Edema in brain Hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 27, 460–468.
Timofeev, I., Nortje, J., Al-Rawi, P. G., Hutchinson, P. J., & Gupta, A. K. (2013). Extracellular brain Ph with or without hypoxia is a marker of profound metabolic derangement and increased mortality after traumatic brain injury. Journal of Cerebral Blood Flow and Metabolism, 33, 422–427.
Tóth, M. O., et al. (2020). Tissue acidosis associated with ischemic stroke to guide neuroprotective drug delivery. Biology, 9, E460.
Tower, J., Pomatto, L. C. D., & Davies, K. J. A. (2020). Sex differences in the response to oxidative and proteolytic stress. Redox Biology, 31, 101488.
Vafadari, B., Salamian, A., & Kaczmarek, L. (2016). MMP-9 in translation: From molecule to brain physiology, pathology, and therapy. Journal of Neurochemistry, 139, 91–114.
Vilalta, A., et al. (2008). Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Medicine, 34, 1384–1392.
Vilalta, A., et al. (2009). Brain contusions induce a strong local overexpression of MMP-9. Results of a pilot study. In H.-J. Steiger (Ed.), Acta neurochirurgica supplements (pp. 415–419). Springer. https://doi.org/10.1007/978-3-211-85578-2_81
Wang, M., Wang, T., Liu, S., Yoshida, D., & Teramoto, A. (2003). The expression of matrix metalloproteinase-2 and-9 in human gliomas of different pathological grades. Brain Tumor Pathology, 20, 65–72.
Wang, Y., et al. (2015). A prodrug-type, MMP-2-targeting Nanoprobe for tumor detection and imaging. Theranostics, 5, 787–795.
Wang, Y., et al. (2016). Electroresponsive nanoparticles improve Antiseizure effect of phenytoin in generalized tonic-Clonic seizures. Neurotherapeutics, 13, 603–613.
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011). Dysregulated pH: A perfect storm for cancer progression. Nature Reviews. Cancer, 11, 671–677.
Whitley, M. J., et al. (2016). A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Science Translational Medicine, 8, 320ra4–320ra4.
Wong, C., et al. (2011). Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proceedings of the National Academy of Sciences, 108, 2426–2431.
Wood, H. (2018). FDA approves patisiran to treat hereditary transthyretin amyloidosis. Nature Reviews. Neurology, 14, 570–570.
Wood, T., & Nance, E. (2019). Disease-directed engineering for physiology-driven treatment interventions in neurological disorders. APL Bioengineering, 3, 040901.
Wu, G., Fang, Y.-Z., Yang, S., Lupton, J. R., & Turner, N. D. (2004). Glutathione metabolism and its implications for health. The Journal of Nutrition, 134, 489–492.
Wu, H., et al. (2020). Sequential targeting in crosslinking Nanotheranostics for tackling the multibarriers of brain Tumors. Advanced Materials, 32, 1903759.
Xi, G., Reiser, G., & Keep, R. F. (2002). The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: Deleterious or protective? Journal of Neurochemistry, 84, 3–9.
Xu, J., et al. (2019). Sequentially site-specific delivery of Thrombolytics and Neuroprotectant for enhanced treatment of ischemic stroke. ACS Nano, 13, 8577–8588.
Yang, L., et al. (2016). Gold nanoparticle-capped mesoporous silica-based H2O2-responsive controlled release system for Alzheimer’s disease treatment. Acta Biomaterialia, 46, 177–190.
Yang, J., et al. (2019). Reactive oxygen species play a biphasic role in brain ischemia. Journal of Investigative Surgery, 32, 97–102.
Yokota, H., et al. (2000). Measurements of cortical cellular pH by intracranial tonometer in severe head injury. Critical Care Medicine, 28, 3275–3280.
Yoo, D., et al. (2017). Core-cross-linked nanoparticles reduce Neuroinflammation and improve outcome in a mouse model of traumatic brain injury. ACS Nano, 11, 8600–8611.
Yu, Y. J., et al. (2011). Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Science Translational Medicine, 3, 84ra44–84ra44.
Zagni, E., Simoni, L., & Colombo, D. (2016). Sex and gender differences in central nervous system-related disorders. Journal of Neuroscience, 2016, 1–13.
Zhang, Z., et al. (2009). Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis, 14, 1289–1298.
Zhang, X.-X., Eden, H. S., & Chen, X. (2012). Peptides in cancer nanomedicine: Drug carriers, targeting ligands and protease substrates. Journal of Controlled Release, 159, 2–13.
Zhang, S., et al. (2020). Autocatalytic delivery of brain tumor–targeting, size-shrinkable nanoparticles for treatment of breast cancer brain metastases. Advanced Functional Materials, 30, 1910651.
Zhang, T., et al. (2021). Reactive oxide species-scavenging lipid-polymer nanoparticles for neuroprotection after spinal cord injury. Applied Materials Today, 24, 101109.
Zhao, B.-Q., et al. (2006). Role of matrix metalloproteinases in delayed cortical responses after stroke. Nature Medicine, 12, 441–445.
Zheng, M., et al. (2019). ROS-responsive polymeric siRNA nanomedicine stabilized by triple interactions for the robust glioblastoma combinational RNAi therapy. Advanced Materials, 31, 1903277.
Zhou, J., Zhang, L., & Tian, Y. (2016). Micro electrochemical pH sensor applicable for real-time Ratiometric monitoring of pH values in rat brains. Analytical Chemistry, 88, 2113–2118.
Zhou, Y., et al. (2020). Targeted delivery of secretory Promelittin via novel poly(lactone-co-β-amino ester) nanoparticles for treatment of breast cancer brain metastases. Advancement of Science, 7, 1901866.
Zou, Y., et al. (2020). Single siRNA Nanocapsules for effective siRNA brain delivery and glioblastoma treatment. Advanced Materials, 32, 2000416.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kudryashev, J.A., Madias, M.I., Kwon, E.J. (2022). Bioresponsive Nanomaterials for CNS Disease. In: Nance, E. (eds) Engineering Biomaterials for Neural Applications. Springer, Cham. https://doi.org/10.1007/978-3-031-11409-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-031-11409-0_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-11408-3
Online ISBN: 978-3-031-11409-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)